Skip to main content
. 2018 May 11;9:137. doi: 10.1186/s13287-018-0878-1

Fig. 3.

Fig. 3

Systemically administered allogeneic MSCs do not accelerate progression of precancerous lesions. At dysplasia stage, hamsters received intracardially vehicle or 0.7 × 106, 7 × 106, or 21 × 106 MSCs/kg. Progression of precancerous lesions was assessed macroscopically (n = 14). MSC mesenchymal stem cell